FMP
F-star Therapeutics, Inc.
FSTX
NASDAQ
Inactive Equity
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
7.12 USD
0 (0%)
Dr. Eliot Richard Forster M.B.A., Ph.D.
Healthcare
Biotechnology
NASDAQ
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
0001566373
US30315R1077
30315R107
Eddeva B920
44 1223 497400
GB
84
May 6, 2016
Mr. James Sandy MPhil
Chief Devel. Officer
0
N/A
Ms. Darlene M. Deptula-Hicks MBA
Chief Financial Officer, Treasurer & Sec...
739.69k
1957
Dr. Eliot Richard Forster M.B.A., Ph.D.
Pres, Chief Executive Officer & Director
866.02k
1966
Lindsey Trickett
Vice President of Investor Relations & C...
0
N/A
Dr. Neil Brewis Ph.d.
Chief Scientific Officer
557.36k
1967
Dr. Louis Kayitalire M.D.
Chief Medical Officer
612.74k
1958
As of December 31, 2024, the total employee count stands at 84, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.